生物医药公司Opko Health与Entera Bio宣布扩大战略合作，双方将携手加速开发针对甲状旁腺功能减退症患者的突破性疗法——全球首创口服长效甲状旁腺激素（PTH）片剂。此次合作拓展标志着两家企业在内分泌疾病治疗领域迈出关键一步，有望为长期依赖钙剂和维生素D补充治疗的患者提供更便捷的用药选择。
甲状旁腺功能减退症是一种罕见的内分泌疾病，其特征是甲状旁腺激素分泌不足，导致血钙水平异常低下。目前标准治疗方案需频繁服用钙剂与活性维生素D，但仍难以完全控制症状。新型口服PTH片剂若研发成功，将成为该领域首个通过口服给药实现长效激素替代的创新疗法，从根本上改善患者生活质量。
通过整合Opko Health在内分泌领域的专业优势与Entera Bio的口服大分子药物递送技术，双方将推进该片剂的临床前研究及后续临床试验。这一合作不仅强化了两家公司的研发管线协同效应，更展现了口服多肽药物递送技术在内分泌治疗领域的应用潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.